ClinicalTrials.gg
Not yet recruitingNCT07951424Updated Nov 20, 2026

Clinical Utility Pilot Of Thyroid GuidePx

An observational study in Papillary Thyroid Cancers, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
78
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 76 studies in Thyroid Cancer, Papillary with a site in United States — 8 open to participants now, 18 under way, 1 of them phase 3. Thyroid Cancer, Papillary · United States.

Started
2027
the only one that year
Observational
9 of 76
3 open now
Primary completion
2029-06
later than 16 of 16 live
Registered
76th of 76
by date
Lead sponsor
5 of 76
M.D. Anderson Cancer Center

Among the 76 studies in Thyroid Cancer, Papillary with a site in United States, this one is the only one that started in 2027, is one of 9 observational ones, reaches primary completion later than 16 of the 16 other live ones, and was the 76th registered.

Thyroid Cancer, Papillary

187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

8 of the 76 studies in Thyroid Cancer, Papillary with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Thyroid Cancer, Papillary with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is learn about the effects of Thyroid GuidePx® on papillary thyroid cancer treatment recommendations when the test result is disclosed after surgery.

Read the detailed description

Primary Objectives:

To determine the decision impact of Thyroid GuidePx® when results are disclosed postoperatively, defined across three prespecified decision domains:

  1. Extent of initial surgery (counterfactual): (i) among patients who actually had a total thyroidectomy, through the post-test clinician survey, whether Thyroid GuidePx® results would have changed surgical extent and lobectomy would have been appropriate. This includes patients who underwent intraoperative conversion from lobectomy to total thyroidectomy due to gross extrathyroidal extension or unexpected central nodal metastases. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation.
  2. Completion thyroidectomy: whether Thyroid GuidePx® results change the recommendation to perform completion thyroidectomy or not to perform completion thyroidectomy.
  3. Adjuvant RAI: Whether Thyroid GuidePx® results change the recommendation to administer postoperative RAI or not to administer postoperative RAI.

Secondary Objectives:

  1. To estimate the proportion of decision changes within each prespecified domain and the net direction (escalation vs de-escalation).
  2. To explore clinician- and patient-reported drivers of decision change.
  3. To assess postoperative decisional regret following disclosure of Thyroid GuidePx® results using the Decisional Regret Scale (DRS), and to explore associations with surgical extent and molecular risk category.
  4. To compare the proportion of patients who had a completion thyroidectomy in patients who underwent Thyroid GuidePx® testing to historical controls.
  5. To compare recurrence outcomes in patients whose treatment was de-escalated based on Thyroid GuidePx® result to matched historical controls at the same institution.
03

Conditions studied

  • Papillary Thyroid Cancers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

UT MD Anderson

Eligibility criteria

Inclusion Criteria:

disease who can potentially be treated with lobectomy will be recruited to the study. Lobectomy-candidate status is determined by the treating physician using standard institutional criteria (e.g., tumor 1-4 cm, cN0/Nx, no gross ETE). Patients may still undergo total thyroidectomy as part of shared decision-making.

Inclusion criteria:

  • Patients aged 18 years or older at the time of enrollment
  • English-speaking
  • Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)
  • Preoperative candidacy for lobectomy

    • Tumor 1 - 4 cm in size
    • No known nodal
    • No gross extrathyroidal extension (ETE) on ultrasound
  • Any of the following intraoperative or surgeon-dependent variations are permitted:

    • Prophylactic ipsilateral central neck dissection performed at the surgeon's discretion
    • Therapeutic central neck dissection for unexpected central node metastases
    • Intraoperative conversion to total thyroidectomy (e.g., gross ETE, multiple large central nodes)
  • Able to undergo intraoperative FNA collection for research testing

Exclusion Criteria:

  • Prior thyroid operation
  • Distant metastatic disease
  • Personal history of thyroid cancer
  • History of whole-body radiation exposure or radiation to the head and neck region
  • Preoperatively known central or lateral lymph node metastasis
  • Receipt of total thyroidectomy is not an exclusion if preoperative features otherwise meet lobectomy-candidate criteria

Patients remain eligible if unexpected central nodal disease is identified intraoperatively or if the surgeon elects to perform a prophylactic ipsilateral central neck dissection, as these scenarios are compatible with initial lobectomy candidacy at MD Anderson.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
78 participants (estimated)
Patient registry
No

Groups and cohorts

  • All Patients

    Eligible participants will be identified during standard preoperative evaluation for thyroid nodules or confirmed PTC, following cytological diagnosis (Bethesda V or VI).

    Procedure: Thyroid GuidePx

Interventions

  • ProcedureThyroid GuidePx

    Participants will be offered enrollment in this study, in which Thyroid GuidePx® will be performed on an intraoperative FNA (ioFNA) collected during surgery, with results disclosed postoperatively.

06

What researchers measure

Primary outcomes

  1. Decision Impact. There are three domain-specific endpoints

    Extent of initial surgery (counterfactual). (i) Among patients who actually had total thyroidectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, would have changed surgical extent. Specifically, if lobectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential de-escalation. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation. b) Completion thyroidectomy. Proportion with a change in recommendation (Yes→No or No→Yes). c) Adjuvant RAI. Proportion with a change in recommendation (Yes→No or No→Yes) and intended dose if Yes.

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Jun 2029, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951424
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Anastasios Maniakas, MD
Contact
amaniakas@mdanderson.org
713-792-4351
Anastasios Maniakas, MD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion